Onxeo Receives Notice of Allowance for a New Patent
Onxeo S.A. Onxeo” or “ the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that it has received from the U.S. Patent and Trademark Office (USPTO), a Notice Allowance for a patent which enhances in the United States the protection of AsiDNA™, its first-in-class inhibitor of tumor DNA repair, in combination with any PARP inhibit...
Source: globenewswire.com